Federal Register / Vol. 88, No. 230 / Friday, December 1, 2023 / Notices 83953 

In compliance with section 

3507(a)(1)(D) of the Paperwork 

Reduction Act of 1995, NIH has 

submitted to OMB a request for review 

and approval of the information 

collection listed below. 

Proposed Collection Title: Assurance 

(Interinstitutional, Foreign, and 

Domestic) and Annual Report, OMB 

#0925–0765, expiration date 11/30/ 

2022, Reinstatement with Change, 

Office of the Director (OD), National 

Institutes of Health (NIH). 

Need and Use of Information 

Collection: The NIH Office of Laboratory 

Welfare (OLAW) is responsible for the 

implementation, general administration, 

and interpretation of the Public Health 

Service (PHS) Policy on Humane Care 

and Use of Laboratory Animals (Policy) 

as codified in 42 CFR 52.8. The PHS 

Policy implements the Health Research 

Extension Act (HREA) of 1985 (Pub. L. 

99–158 as codified in 42 U.S.C. 289d). 

The PHS Policy requires entities that 

conduct research involving vertebrate 

animals using PHS funds to have an 

Institutional Animal Care and Use 

Committee (IACUC), provide assurance 

that requirements of the Policy are met, 

and submit an annual report. 

Institutions in foreign countries comply 

with the PHS Policy or provide 

evidence that acceptable standards for 

the humane care and use of the animals 

in PHS-conducted or -supported 

activities will be met. An institution’s 

animal care and use program is 

described in the Animal Welfare 

Assurance (Assurance) document and 

sets forth institutional compliance with 

PHS Policy. The purpose of the 

Assurance (Interinstitutional, Foreign, 

and Domestic) and Annual Report is to 

provide OLAW with documentation to 

satisfy the requirements of the HREA, 

illustrate institutional adherence to PHS 

Policy, and enable OLAW to carry out 

its mission to ensure the humane care 

and use of animals in PHS-supported 

research, testing, and training, thereby 

contributing to the quality of PHSsupported activities. 

OMB approval is requested for 3 

years. There are no costs to respondents 

other than their time. The total 

estimated annualized burden hours are 

9,219. 

ESTIMATED ANNUALIZED BURDEN HOURS

Form name Type of respondents Number of 

respondents 

Number of 

responses per 

respondent 

Average 

burden per 

response 

(in hours) 

Total annual 

burden hours 

Domestic Assurance ................................................................................... Renewal and New ....... 235 1 30 7,050 

Domestic Annual Report ............................................................................. All Domestic ................. 890 1 90/60 1,335 

Foreign Assurance ...................................................................................... Renewal and New ....... 67 1 90/60 101 

Foreign Annual Report ............................................................................... All Foreign .................... 335 1 1 335 

Interinstitutional Assurance for Foreign Performance Site or Interinstitutional Assurance Triad for Foreign Performance Site.Foreign ......................... 46 1 30/60 23 

Interinstitutional Assurance for Domestic Performance Site or Interinstitutional Assurance Triad for Domestic Performance Site.Domestic ...................... 750 1 30/60 375 

Total ..................................................................................................... ...................................... 2,323 6 .................... 9,219 

Dated: November 22, 2023. 

Lawrence A. Tabak, 

Principal Deputy Director, National Institutes 

of Health. 

[FR Doc. 2023–26400 Filed 11–30–23; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Cancer Institute; Amended 

Notice of Meeting 

Notice is hereby given of a change in 

the meeting of the National Cancer 

Institute Initial Review Group; Career 

Development Study Section (J), 

February 28, 2024, 10:00 a.m. to 

February 29, 2024, 06:00 p.m., National 

Cancer Institute Shady Grove, 9609 

Medical Center Drive, Room 7W624, 

Rockville, Maryland 20850 which was 

published in the Federal Register on 

November 2, 2023, FR Doc. 2023–24225, 

88 FR 75294. 

This notice is being amended to 

change the start time of the meeting 

from 10:00 a.m. to 9:00 a.m. on February 

28, 2024. The meeting dates and 

location will stay the same. The meeting 

is closed to the public. 

Dated: November 27, 2023. 

Melanie J. Pantoja, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2023–26451 Filed 11–30–23; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Neurological 

Disorders and Stroke; Amended Notice 

of Meeting 

Notice is hereby given of a change in 

the meeting of the National Institute of 

Neurological Disorders and Stroke 

Special Emphasis Panel, November 27, 

2023, 10:00 a.m. to November 28, 2023, 

05:00 p.m., National Institutes of Health, 

Neuroscience Center, 6001 Executive 

Boulevard, Rockville, MD 20852 which 

was published in the Federal Register 

on November 13, 2023, FR Doc 2023– 

24961, 88 FR 77597. 

This notice is being amended to 

change the dates of this two-day 

meeting to December 14, 2023, and 

December 15, 2023. The meeting time 

remains the same. The meeting is closed 

to the public. 

Dated: November 28, 2023. 

David W. Freeman, 

Supervisory Program Analyst, Office of 

Federal Advisory Committee Policy. 

[FR Doc. 2023–26450 Filed 11–30–23; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Substance Abuse and Mental Health 

Services Administration 

Current List of HHS-Certified 

Laboratories and Instrumented Initial 

Testing Facilities Which Meet Minimum 

Standards To Engage in Urine and Oral 

Fluid Drug Testing for Federal 

Agencies 

AGENCY: Substance Abuse and Mental 

Health Services Administration, HHS. 

ACTION: Notice. 

SUMMARY: The Department of Health and 

Human Services (HHS) notifies Federal 

agencies of the laboratories and 

Instrumented Initial Testing Facilities 


lotter on DSK11XQN23PROD with NOTICES1
83954 Federal Register / Vol. 88, No. 230 / Friday, December 1, 2023 / Notices 

(IITFs) currently certified to meet the 

standards of the Mandatory Guidelines 

for Federal Workplace Drug Testing 

Programs using Urine or Oral Fluid 

(Mandatory Guidelines). 

FOR FURTHER INFORMATION CONTACT: 

Anastasia Flanagan, Division of 

Workplace Programs, SAMHSA/CSAP, 

5600 Fishers Lane, Room 16N06B, 

Rockville, Maryland 20857; 240–276– 

2600 (voice); Anastasia.Flanagan@

samhsa.hhs.gov (email). 

SUPPLEMENTARY INFORMATION: In 

accordance with Section 9.19 of the 

Mandatory Guidelines, a notice listing 

all currently HHS-certified laboratories 

and IITFs is published in the Federal 

Register during the first week of each 

month. If any laboratory or IITF 

certification is suspended or revoked, 

the laboratory or IITF will be omitted 

from subsequent lists until such time as 

it is restored to full certification under 

the Mandatory Guidelines. 

If any laboratory or IITF has 

withdrawn from the HHS National 

Laboratory Certification Program (NLCP) 

during the past month, it will be listed 

at the end and will be omitted from the 

monthly listing thereafter. 

This notice is also available on the 

internet at https://www.samhsa.gov/ 

workplace/resources/drug-testing/ 

certified-lab-list. 

The Department of Health and Human 

Services (HHS) notifies Federal agencies 

of the laboratories and Instrumented 

Initial Testing Facilities (IITFs) 

currently certified to meet the standards 

of the Mandatory Guidelines for Federal 

Workplace Drug Testing Programs 

(Mandatory Guidelines) using Urine and 

of the laboratories currently certified to 

meet the standards of the Mandatory 

Guidelines using Oral Fluid. 

The Mandatory Guidelines using 

Urine were first published in the 

Federal Register on April 11, 1988 (53 

FR 11970), and subsequently revised in 

the Federal Register on June 9, 1994 (59 

FR 29908); September 30, 1997 (62 FR 

51118); April 13, 2004 (69 FR 19644); 

November 25, 2008 (73 FR 71858); 

December 10, 2008 (73 FR 75122); April 

30, 2010 (75 FR 22809); and on January 

23, 2017 (82 FR 7920). 

The Mandatory Guidelines using Oral 

Fluid were first published in the 

Federal Register on October 25, 2019 

(84 FR 57554) with an effective date of 

January 1, 2020. 

The Mandatory Guidelines were 

initially developed in accordance with 

Executive Order 12564 and section 503 

of Public Law 100–71 and allowed urine 

drug testing only. The Mandatory 

Guidelines using Urine have since been 

revised, and new Mandatory Guidelines 

allowing for oral fluid drug testing have 

been published. The Mandatory 

Guidelines require strict standards that 

laboratories and IITFs must meet in 

order to conduct drug and specimen 

validity tests on specimens for Federal 

agencies. HHS does not allow IITFs to 

conduct oral fluid testing. 

To become certified, an applicant 

laboratory or IITF must undergo three 

rounds of performance testing plus an 

on-site inspection. To maintain that 

certification, a laboratory or IITF must 

participate in a quarterly performance 

testing program plus undergo periodic, 

on-site inspections. 

Laboratories and IITFs in the 

applicant stage of certification are not to 

be considered as meeting the minimum 

requirements described in the HHS 

Mandatory Guidelines using Urine and/ 

or Oral Fluid. An HHS-certified 

laboratory or IITF must have its letter of 

certification from HHS/SAMHSA 

(formerly: HHS/NIDA), which attests 

that the test facility has met minimum 

standards. HHS does not allow IITFs to 

conduct oral fluid testing. 

HHS-Certified Laboratories Approved 

To Conduct Oral Fluid Drug Testing 

In accordance with the Mandatory 

Guidelines using Oral Fluid dated 

October 25, 2019 (84 FR 57554), the 

following HHS-certified laboratories 

meet the minimum standards to conduct 

drug and specimen validity tests on oral 

fluid specimens: 

At this time, there are no laboratories 

certified to conduct drug and specimen 

validity tests on oral fluid specimens. 

HHS-Certified Instrumented Initial 

Testing Facilities Approved To Conduct 

Urine Drug Testing 

In accordance with the Mandatory 

Guidelines using Urine dated January 

23, 2017 (82 FR 7920), the following 

HHS-certified IITFs meet the minimum 

standards to conduct drug and specimen 

validity tests on urine specimens: 

Dynacare,* 6628 50th Street NW, 

Edmonton, AB Canada T6B 2N7, 780– 

784–1190, (Formerly: GammaDynacare Medical Laboratories) 

HHS-Certified Laboratories Approved 

To Conduct Urine Drug Testing 

In accordance with the Mandatory 

Guidelines using Urine dated January 

23, 2017 (82 FR 7920), the following 

HHS-certified laboratories meet the 

minimum standards to conduct drug 

and specimen validity tests on urine 

specimens: 

Alere Toxicology Services, 1111 Newton 

St., Gretna, LA 70053, 504–361–8989/ 

800–433–3823, (Formerly: Kroll 

Laboratory Specialists, Inc., 

Laboratory Specialists, Inc.) 

Alere Toxicology Services, 450 

Southlake Blvd., Richmond, VA 

23236, 804–378–9130, (Formerly: 

Kroll Laboratory Specialists, Inc., 

Scientific Testing Laboratories, Inc.; 

Kroll Scientific Testing Laboratories, 

Inc.) 

Clinical Reference Laboratory, Inc., 8433 

Quivira Road, Lenexa, KS 66215– 

2802, 800–445–6917 

Desert Tox, LLC, 5425 E Bell Rd, Suite 

125, Scottsdale, AZ 85254, 602–457– 

5411/623–748–5045 

DrugScan, Inc., 200 Precision Road, 

Suite 200, Horsham, PA 19044, 800– 

235–4890 

Dynacare,* 245 Pall Mall Street, 

London, ONT, Canada N6A 1P4, 519– 

679–1630, (Formerly: GammaDynacare Medical Laboratories) 

ElSohly Laboratories, Inc., 5 Industrial 

Park Drive, Oxford, MS 38655, 662– 

236–2609 

LabOne, Inc. d/b/a Quest Diagnostics, 

10101 Renner Blvd., Lenexa, KS 

66219, 913–888–3927/800–873–8845, 

(Formerly: Quest Diagnostics 

Incorporated; LabOne, Inc.; Center for 

Laboratory Services, a Division of 

LabOne, Inc.) 

Laboratory Corporation of America, 

1225 NE 2nd Ave., Portland, OR 

97232, 503–413–5295/800–950–5295, 

(Formerly: Legacy Laboratory Services 

Toxicology MetroLab) 

Laboratory Corporation of America 

Holdings, 7207 N. Gessner Road, 

Houston, TX 77040, 713–856–8288/ 

800–800–2387 

Laboratory Corporation of America 

Holdings, 69 First Ave., Raritan, NJ 

08869, 908–526–2400/800–437–4986, 

(Formerly: Roche Biomedical 

Laboratories, Inc.) 

Laboratory Corporation of America 

Holdings, 1904 TW Alexander Drive, 

Research Triangle Park, NC 27709, 

919–572–6900/800–833–3984, 

(Formerly: LabCorp Occupational 

Testing Services, Inc., CompuChem 

Laboratories, Inc.; CompuChem 

Laboratories, Inc., A Subsidiary of 

Roche Biomedical Laboratory; Roche 

CompuChem Laboratories, Inc., A 

Member of the Roche Group) 

Laboratory Corporation of America 

Holdings, 1120 Main Street, 

Southaven, MS 38671, 866–827–8042/ 

800–233–6339, (Formerly: LabCorp 

Occupational Testing Services, Inc.; 

MedExpress/National Laboratory 

Center) 

MedTox Laboratories, Inc., 402 W 

County Road D, St. Paul, MN 55112, 

651–636–7466/800–832–3244 

Minneapolis Veterans Affairs Medical 

Center, Forensic Toxicology 


lotter on DSK11XQN23PROD with NOTICES1
Federal Register / Vol. 88, No. 230 / Friday, December 1, 2023 / Notices 83955 

Laboratory, 1 Veterans Drive, 

Minneapolis, MN 55417, 612–725– 

2088. Testing for Veterans Affairs 

(VA) Employees Only 

Omega Laboratories, Inc.,* 2150 

Dunwin Drive, Unit 1 & 2, 

Mississauga, ON, Canada L5L 5M8, 

289–919–3188 

Pacific Toxicology Laboratories, 9348 

DeSoto Ave., Chatsworth, CA 91311, 

800–328–6942, (Formerly: Centinela 

Hospital Airport Toxicology 

Laboratory) 

Phamatech, Inc., 15175 Innovation 

Drive, San Diego, CA 92128, 888– 

635–5840 

Quest Diagnostics Incorporated, 400 

Egypt Road, Norristown, PA 19403, 

610–631–4600/877–642–2216, 

(Formerly: SmithKline Beecham 

Clinical Laboratories; SmithKline BioScience Laboratories) 

US Army Forensic Toxicology Drug 

Testing Laboratory, 2490 Wilson St., 

Fort George G. Meade, MD 20755– 

5235, 301–677–7085. Testing for 

Department of Defense (DoD) 

Employees Only 

* The Standards Council of Canada 

(SCC) voted to end its Laboratory 

Accreditation Program for Substance 

Abuse (LAPSA) effective May 12, 1998. 

Laboratories certified through that 

program were accredited to conduct 

forensic urine drug testing as required 

by U.S. Department of Transportation 

(DOT) regulations. As of that date, the 

certification of those accredited 

Canadian laboratories will continue 

under DOT authority. The responsibility 

for conducting quarterly performance 

testing plus periodic on-site inspections 

of those LAPSA-accredited laboratories 

was transferred to the U.S. HHS, with 

the HHS’ NLCP contractor continuing to 

have an active role in the performance 

testing and laboratory inspection 

processes. Other Canadian laboratories 

wishing to be considered for the NLCP 

may apply directly to the NLCP 

contractor just as U.S. laboratories do. 

Upon finding a Canadian laboratory to 

be qualified, HHS will recommend that 

DOT certify the laboratory (61 FR 37015, 

July 16, 1996) as meeting the minimum 

standards of the Mandatory Guidelines 

published in the Federal Register on 

January 23, 2017 (82 FR 7920). After 

receiving DOT certification, the 

laboratory will be included in the 

monthly list of HHS-certified 

laboratories and participate in the NLCP 

certification maintenance program. 

Anastasia D. Flanagan, 

Public Health Advisor, Division of Workplace 

Programs. 

[FR Doc. 2023–26428 Filed 11–30–23; 8:45 am] 

BILLING CODE 4160–20–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Substance Abuse and Mental Health 

Services Administration 

Agency Information Collection 

Activities: Submission for OMB 

Review; Comment Request 

Periodically, the Substance Abuse and 

Mental Health Services Administration 

(SAMHSA) will publish a summary of 

information collection requests under 

OMB review, in compliance with the 

Paperwork Reduction Act (44 U.S.C. 

chapter 35). To request a copy of these 

documents, call the SAMHSA Reports 

Clearance Officer on (240) 276–0361. 

Proposed Project: 988 Cooperative 

Agreements Monitoring Program (OMB 

No. 0930–0290)—New ICR 

The Substance Abuse and Mental 

Health Services Administration 

(SAMHSA) is seeking Office of 

Management and Budget (OMB) 

Emergency approval for new 

information collection activities for 

monitoring all of SAMHSA’s 988 

Cooperative Agreements. The collection 

of this information is critical to 

successfully oversee operational 

response and quality of service through 

the 988 Suicide and Crisis Lifeline to 

ensure connections to care for 

individuals in suicidal crisis or 

emotional distress contacting in for 988 

phone, chat, and text support for 

connecting local, state/territory and 

national outcomes and monitoring 

contractual obligations for current and 

future 988 grant programs. Much of this 

information is already embedded in the 

current 988 Suicide and Crisis Lifeline 

network administrator grants, the 988 

state and territory grant program, or the 

988 Tribal Response grant program. 

Congress designated 988 in 2020 and 

the Lifeline transitioned to the 3-digit 

number in July 2022. As a part of the 

federal government’s commitment to 

addressing the mental health crisis in 

America, unprecedented federal 

resources have been invested to scale up 

crisis centers in support of 988. In 

section 1103(a)(2)(B) of the 

Consolidated Appropriations Act, 2023, 

Congress called for enhanced program 

evaluation, including performance 

measures to assess program response 

and improve readiness and performance 

of the service, including review of each 

contact to ensure timely connection of 

service and quality provision in line 

with evidence-based care. To help meet 

the standards and requirements set forth 

in statute, ongoing communication of 

key outcomes within this OMB request 

must be received and reviewed to 

ensure connection and quality of care 

through 988. 

The information being collected will 

be used by SAMHSA to ensure 

individuals in suicidal crisis can contact 

988 Suicide and Crisis Lifeline and are 

connected to crisis centers provided 

evidence-based care and able to receive 

critical resource referral and linkage, 

including opportunities for mobile crisis 

support, crisis receiving and stabilizing 

facilities, peer respite centers and 

withdrawal management services. The 

four programs to be monitored and 

evaluated include the Tribal 

Cooperative Agreements, State and 

Territory Cooperative Agreements, 988 

Crises Center Follow-up Cooperative 

Agreements, and the 988 Lifeline 

Administrator. 

The purpose of the Tribal Cooperative 

Agreements is to provide resources to 

improve response to 988 contacts 

(including calls, chats, and texts) 

originating in Tribal communities and/ 

or activated by American Indians/ 

Alaska Natives. The information 

collection instruments include Tribal 

Government: Semi Annual Progress 

Report, Tribal Government: Monthly 

Meeting Agenda, Tribal Government: 

Quality Improvement Plan. 

The purpose of the State and Territory 

Cooperative Agreements is to improve 

state and territory response to 988 

contacts (including calls, chats, and 

texts) originating in the state/territory. 

The information collection instruments 

include State/Territory: Monthly Key 

Metrics, State/Territory: Quarterly 

Report Template, State/Territory: 

Programmatic QI Plan (Annual 

Collection), State/Territory: Monthly 

Meeting Call Agenda, State/Territory: 

Chat and Text Report (Annual 

Collection), State/Territory: 

Communications Plan (Annual 

Collection), State/Territory: 

Sustainability Plan (Annual Collection), 

State/Territory: Mobile Crisis and 988– 

911 reports (Annual Collection). 

The purpose of the 988 Crisis Center 

Follow Up Cooperative Agreements is to 

provide a crisis center response that 

ensures the systematic follow-up of 

suicidal persons who contact a 988 

Suicide and Crisis Lifeline (988 Lifeline) 

Crisis Center; provides enhanced 

coordination of crisis stabilization, 

crisis respite, mobile crisis outreach 

(MCO) response services and other 

services on the crisis continuum of care; 

reduces unnecessary police engagement 

and; improves connections for high-risk 

populations. The information collection 

instruments include Crisis Center Data 

Reporting Elements and Crisis Center 

Monthly Agenda Template. 


lotter on DSK11XQN23PROD with NOTICES1